Other languages Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Market Closed - Sao Paulo Other stock markets 15:25:03 13/06/2024 BST			5-day change	1st Jan Change
57.22 ^BRL	-1.87%		-1.31%	+14.55%

06-14	Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	DJ
06-14	Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	06-14
Sector Update: Health Care Stocks Softer Friday Afternoon	06-14
Wall Street finit contrastée, nouveaux records pour Nasdaq et S&P 500	06-13
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	06-13
AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	06-05
Amgen's drug meets main goal in late-stage study for rare disease	06-05
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)	06-05
Amgen Inc. Appoints Dr. Mary E. Klotman as Director	06-03
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28
Previsiones de venta de medicamentos para adelgazar suben a 150.000 millones de dólares	05-28
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28
Sandoz : AMM pour Wyost et Jubbonti dans l'UE	05-22
Un test de Roche reçoit la désignation de dispositif révolutionnaire aux USA	05-22
Sandoz: feu vert de la Commission européenne pour Wyost et Jubbonti	05-22
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test	05-22
Roche erhält von FDA "Breakthrough Device Designation" für Bluttest	05-22
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results	05-20
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease	05-19
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer	05-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amgen Inc. Sao Paulo

Equities

AMGN34

BRAMGNBDR004

Other languages

Filters